LINC 2020: XTOSI study interim findings suggest “highly promising” safety and efficacy of sirolimus DCB

Edward Choke (Singapore) talks to BLearning Peripheral at LINC 2020 (Leipzig Interventional Course; 28–31 January 2020, Leipzig, Germany) about the first-in-man clinical study—XTOSI—which looked at the safety and efficacy of a sirolimus drug-coated balloon (DCB) in the treatment of peripheral arterial disease.

The interim findings showed that primary patency at six months in the XTOSI below-the-knee (BTK) patients was 74%. This, notes Choke, is “highly promising”, particularly when compared to a recent study by separate investigators which looked at a paclitaxel DCB in BTK patients and showed patency of just 40% at six months. Choke outlines some of the challenges with the critical limb ischaemia (CLI) patient cohort, including the strong prevalence of diabetes (90% of patients) and the “complexity of the lesions themselves”.

He concludes by discussing the next steps, including the need to gather level one data from a larger population of patients and also highlights two upcoming randomised controlled trials, FUTURE-SFA and FUTURE-BTK.

Subscribe to receive BLearning videos here:

Choke, Edward

Edward Choke is presently a Senior Consultant Vascular and Endovascular Surgeon at Sengkang General Hospital and Singapore General Hospital. He graduated with first class honours MBBS from the University of Sydney and undertook specialist training in General and Vascular Surgery in Oxford between 2006 and 2010.

Choke was one of three UK trainees in 2012 to receive the competitive British Society of Endovascular Therapy Endovascular Fellowship which advanced his skills in peripheral angioplasties and hybrid techniques for complex multilevel occlusive or stenotic disease.

Add comment

Editor’s Peripheral Pick

    Subscribeto receive the very best in medical videos